 Protalix BioTherapeutics Inc NYSE: PLX and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A, have announced final results from the BRIGHT Phase 3 trial of pegunigalsidase alfa PRX102 for Fabry disease. The results indicate that treatment with 2 mgkg. 